Skip to search formSkip to main contentSkip to account menu

CMFVP protocol

Known as: Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone/Vincristine, CVFMP protocol, VPCMF 
A combination of agents containing cyclophosphamide, fluorouracil, methotrexate, prednisone and vincristine.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1998
Highly Cited
1998
PURPOSE To determine the significance of plasma c-erbB-2 levels to assess the extent of disease spread and to predict the… 
Highly Cited
1996
Highly Cited
1996
PURPOSE To compare two cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP) regimens with a… 
1993
1993
PURPOSE To determine if prolonged adjuvant treatment (2 years v 1 year) with combination chemotherapy (cyclophosphamide… 
1993
1993
Twenty-two women (17 pre- and 5 postmenopausal) with nodepositive, stage II breast carcinoma were treated with adjuvant… 
1989
1989
Based on favorable results we reported earlier with the CAP regimen in breast cancer (CAP vs CMFVP), the present study compared… 
1985
1985
Women treated by mastectomy for node-positive breast carcinoma were randomly assigned to receive an induction course and 2 years… 
1985
1985
The prospective controlled Phase III clinical trial tested the therapeutic value of the cis-platinum-adriamycin-cyclophosphamide… 
1984
1984
  • C. Tormey
  • 1984
  • Corpus ID: 28746605
The initial results of the comparison of no systemic treatment to l-phenylalanine mustard (l-PAM) and cyclophosphamide… 
Highly Cited
1982
Highly Cited
1982
The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with…